HDAC inhibitors in cancer biology: Emerging mechanisms and clinical applications

Immunology and Cell Biology

Volumn 90, Issue 1, 2012, Pages 85-94

  Khan, Omar ^a   La Thangue, Nicholas B ^a  

^a Laboratory of Cancer Biology   (United Kingdom)

Author keywords

biomarker; cancer; cell death; clinical; HDAC inhibitor

Indexed keywords

ABEXINOSTAT; BELINOSTAT; CARBOPLATIN; CHLOROQUINE; GEMCITABINE; GIVINOSTAT; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 10; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE 5; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE 7; HISTONE DEACETYLASE 9; HISTONE DEACETYLASE INHIBITOR; HISTONE H2A; HISTONE H2B; LUCANTHONE; LYSINE; MOCETINOSTAT; PACLITAXEL; PANOBINOSTAT; PIVALOYLOXYMETHYL BUTYRATE; RESMINOSTAT; ROMIDEPSIN; TAMOXIFEN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT;

ACETYLATION; ACUTE GRANULOCYTIC LEUKEMIA; ADVANCED CANCER; AGGRESOME; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AUTOPHAGY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELLULAR DISTRIBUTION; COLON CANCER; COLORECTAL CANCER; CUTANEOUS T CELL LYMPHOMA; DEACETYLATION; DNA TRANSCRIPTION; DOUBLE STRANDED DNA BREAK; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE EXPRESSION REGULATION; GLIOBLASTOMA; HEAD AND NECK CANCER; HEMATOLOGIC MALIGNANCY; HETEROCHROMATIN; HODGKIN DISEASE; HUMAN; LIVER CELL CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MANTLE CELL LYMPHOMA; MISFOLDED PROTEIN RESPONSE; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; PERIPHERAL T CELL LYMPHOMA; PHASE 2 CLINICAL TRIAL (TOPIC); PROGNOSIS; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN MODIFICATION; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; THROMBOCYTE DISORDER; THYMIC CARCINOMA; THYMUS CANCER; THYROID CANCER; UNSPECIFIED SIDE EFFECT;

ACETYLATION; ANTINEOPLASTIC AGENTS; DEPSIPEPTIDES; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; LYMPHOMA, T-CELL; NEOPLASMS;

EID: 84855471990     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2011.100     Document Type: Review

References (129)

1. Marks PA. The clinical development of histone deacetylase inhibitors as targeted anticancerdrugs. Expert Opin Investig Drugs2010; 19: 1049-1066.
2. Inche AG, La Thangue NB. Chromatin control and cancer-drug discovery: realizing the promise. Drug Discov Today2006; 11: 97-109. (Pubitemid 43375960)
3. Kouzarides T.Chromatin modifications and their function. Cell2007; 128: 693-705. (Pubitemid 46273577)
4. Spotswood HT, Turner BM. An increasingly complex code. J Clin Invest 2002; 110: 577-582. (Pubitemid 34988778)
5. Glozak MA, Sengupta N, Zhang X, Seto E. Acetylation and deacetylation of non-histone proteins. Gene2005; 363: 15-23. (Pubitemid 41691888)
6. Liu T, Liu PY, Marshall GM. Thecritical roleoftheclass III histone deacetylase SIRT1 in cancer. Cancer Res 2009; 69: 1702-1705.
7. Witt O, Deubzer HE, Milde T, Oehme I. HDAC family: what are the cancer relevant targets? Cancer Lett 2009; 277: 8-21.
8. Montgomery RL, Davis CA, Potthoff MJ, Haberland M, Fielitz J, Qi X etal. Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility. Genes Dev2007; 21: 1790-1802. (Pubitemid 47076478)
9. Marchion DC, Bicaku E, Turner JG, Schmitt ML, Morelli DR, Munster PN. HDAC2 regulates chromatin plasticity and enhances DNA vulnerability. Mol Cancer Ther 2009; 8: 794-801.
10. Miller KM, Tjeertes JV, Coates J, Legube G, Polo SE, Britton S et al. Human HDAC1 and HDAC2 function in the DNA-damage response to promote DNA nonhomologous end-joining. Nat Struct Mol Biol 2010; 17: 1144-1151.
11. Bhaskara S, Chyla BJ, Amann JM, Knutson SK, Cortez D, Sun ZW etal. Deletion of histone deacetylase 3 reveals critical roles in S phase progression and DNA damage control. Mol Cell 2008; 30: 61-72. (Pubitemid 351470157)
12. De Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 2003; 370(Pt3): 737-749. (Pubitemid 36399066)
13. Zhang CL, Mc Kinsey TA, Chang S, Antos CL, Hill JA, Olson EN. Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell 2002; 110: 479-488. (Pubitemid 35232291)
14. Vega RB, Matsuda K,Oh J, Barbosa AC, Yang X, Meadows E et al. Histonedeacetylase 4 control schondrocyte hypertrophy durings keletogenesis. Cell 2004; 119: 555-566.
15. Dequiedt F, Kasler H, Fischle W, Kiermer V, Weinstein M, Herndier BG et al. HDAC7, a thymus-specific class II histone deacetylase, regulates Nur77 transcription and TCR-mediated apoptosis. Immunity 2003; 18: 687-698. (Pubitemid 36588585)
16. Urbich C, Rossig L, Kaluza D, Potente M, Boeckel JN, Knau A et al. HDAC5 is a repressor of angiogenesis and determines the angiogenic gene expression pattern of endothelial cells. Blood 2009; 113: 5669-5679.
17. Boyault C, Gilquin B, Zhang Y, Rybin V, Garman E, Meyer-Klaucke W et al. HDAC6-p97/VCP controlled polyubiquitin chain turnover. EMBOJ 2006; 25: 3357-3366. (Pubitemid 44141793)
18. Kawaguchi Y, Kovacs JJ, Mc Laurin A, Vance JM, Ito A, Yao TP. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded proteinstress. Cell 2003; 115: 727-738. (Pubitemid 38030301)
19. Park JH, Kim SH, Choi MC, Lee J, Oh DY, Im SA et al. Class II histone deacetylases play pivotal roles in heat shock protein 90-mediated proteasomal degradation of vascular endothelial growth factor receptors. Biochem Biophys Res Commun 2008; 368: 318-322.
20. Kotian S, Liyanarachchi S, Zelent A, Parvin JD. Histone deacetylases 9 and 10 are required for homologous recombination. J Biol Chem 2011; 286: 7722-7726.
21. Finnin MS, Donigian JR, Cohen A, Richon VM, Rifkind RA, Marks PA et al. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 1999; 401: 188-193. (Pubitemid 29436325)
22. Johnstone RW, Licht JD. Histone deacetylase inhibitors in cancer therapy: is tran-scriptiontheprimarytarget? Cancer Cell 2003; 4: 13-18. (Pubitemid 36904157)
23. Peart MJ, Smyth GK, van Laar RK, Bowtell DD, Richon VM, Marks PA et al. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc Natl Acad Sci USA 2005; 102: 3697-3702. (Pubitemid 40354674)
24. Zhao Y, Tan J, Zhuang L, Jiang X, Liu ET, Yu Q. Inhibitors of histone deacetylases targetthe Rb-E2F1 pathway for apoptosis inductionthrough activation of proapoptotic protein Bim. Proc Natl Acad Sci USA 2005; 102: 16090-16095. (Pubitemid 41552872)
25. Eot-Houllier G, Fulcrand G, Magnaghi-Jaulin L, Jaulin C. Histone deacetylase inhibitors and genomic instability. Cancer Lett 2009; 274: 169-176.
26. Bakkenist CJ, Kastan MB. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 2003; 421: 499-506. (Pubitemid 36168436)
27. Adimoolam S, Sirisawad M, Chen J, Thiemann P, Ford JM, Buggy JJ. HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination. Proc Natl Acad Sci USA 2007; 104: 19482-19487.
28. Zhang Y, Carr T, Dimtchev A, Zaer N, Dritschilo A, Jung M. Attenuated DNA damage repair by trichostatin A through BRCA1 suppression. Radiat Res 2007; 168: 115-124. (Pubitemid 351292932)
29. Petruccelli LA, Dupere-Richer D, Pettersson F, Retrouvey H, Skoulikas S, Miller Jr WH. Vorinostat induces reactive oxygen species and DNA damage in acute myeloid leukemia cells. PLo S One 2011; 6: e20987.
30. Bhalla S, Balasubramanian S, David K, Sirisawad M, Buggy J, Mauro L et al. PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappa B mechanisms and is synergistic with bortezomib in lymphoma cells. Clin Cancer Res 2009; 15: 3354-3365.
31. Rosato RR, Kolla SS, Hock SK, Almenara JA, Patel A, Amin S et al. Histone deacetylase inhibitors activate NF-kappa B in human leukemia cells through an ATM/NEMO-related pathway. J Biol Chem 2010; 285: 10064-10077.
32. Rosato RR, Almenara JA, Grant S. The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated bygeneration of reactiveoxygen speciesand inductionof p21CIP1/WAF1 1. Cancer Res 2003; 63: 3637-3645. (Pubitemid 36793047)
33. Feng R, Oton A, Mapara MY, Anderson G, Belani C, Lentzsch S. The histone deacetylase inhibitor, PXD101, potentiates bortezomib-induced anti-multiple mye-loma effect by induction of oxidative stress and DNA damage. Br J Haematol 2007; 139: 385-397. (Pubitemid 47512171)
34. Dasmahapatra G, Lembersky D, Son MP, Attkisson E, Dent P, Fisher RI et al. Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivo. Mol Cancer Ther 2011; 10: 1686-1697.
35. Taddei A, Maison C, Roche D, Almouzni G. Reversible disruption of pericentric heterochromatin and centromere function by inhibiting deacetylases. Nat Cell Biol 2001; 3: 114-120. (Pubitemid 32118363)
36. Stevens FE, Beamish H, Warrener R, Gabrielli B. Histone deacetylase inhibitors inducemitoticslippage. Oncogene 2008; 27: 1345-1354.
37. Li Y, Kao GD, Garcia BA, Shabanowitz J, Hunt DF, Qin J et al. A novel histone deacetylase pathway regulates mitosis by modulating Aurora B kinase activity. Genes Dev 2006; 20: 2566-2579. (Pubitemid 44396841)
38. Dickinson M, Johnstone RW, Prince HM. Histone deacetylase inhibitors: potential targetsresponsiblefortheiranti-cancereffect. Invest New Drugs 2010; 28: Suppl 1: S3-20.
39. Borbone E, Berlingieri MT, De Bellis F, Nebbioso A, Chiappetta G, Mai A et al. Histone deacetylase inhibitors induce thyroid cancer-specific apoptosis through proteasome-dependent inhibitionof TRAILdegradation. Oncogene 2010; 29: 105-116.
40. Nebbioso A, Clarke N, Voltz E, Germain E, Ambrosino C, Bontempo P et al. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemiacells. Nat Med 2005; 11: 77-84. (Pubitemid 40215841)
41. Srivastava RK, Kurzrock R, Shankar S. MS-275 sensitizes TRAIL-resistant breast cancer cells, inhibits angiogenesis and metastasis, and reverses epithelial-mesench-ymal transition in vivo. Mol Cancer Ther 2010; 9: 3254-3266.
42. Frew AJ, Lindemann RK, Martin BP, Clarke CJ, Sharkey J, Anthony DA et al. Combination therapy of established cancer using a histone deacetylase inhibitor anda TRAILreceptoragonist. Proc Natl Acad Sci USA 2008; 105: 11317-11322.
43. Burz C, Berindan-Neagoe I, Balacescu O, Irimie A. Apoptosis in cancer: key molecular signaling pathways and therapy targets. Acta Oncol 2009; 48: 811-821.
44. Rikiishi H. Autophagic and apoptotic effects of HDAC inhibitors on cancer cells. JBiomed Biotechnol 2011; 2011: 830260.
45. Kerbel RS. Tumorangiogenesis. N Engl J Med 2008; 358: 2039-2049.
46. Kim SH, Jeong JW, Park JA, Lee JW, Seo JH, Jung BK et al. Regulation of the HIF-1alpha stability by histone deacetylases. Oncol Rep 2007; 17: 647-651.
47. Kato H, Tamamizu-Kato S, Shibasaki F. Histone deacetylase 7 associates with hypoxia-inducible factor 1alpha and increases transcriptional activity. J Biol Chem 2004; 279:41966-41974. (Pubitemid 39313647)
48. Kong X, Lin Z, Liang D, Fath D,Sang N, Caro J. Histonedeacetylaseinhibitorsinduce VHL and ubiquitin-independent proteasomal degradation of hypoxia-inducible factor 1alpha. Mol Cell Biol 2006; 26: 2019-2028. (Pubitemid 43346906)
49. Li X, Zhang K, Li Z. Unfolded protein response in cancer: the physician's perspective. J Hematol Oncol 2011; 4: 8.
50. Rao R, Fiskus W, Yang Y, Lee P, Joshi R, Fernandez P et al. HDAC6 inhibition enhances 17-AAG\-mediated abrogation of hsp90 chaperone function in human leukemiacells. Blood 2008; 112: 1886-1893.
51. Fotheringham S, Epping MT, Stimson L, Khan O, Wood V, Pezzella F et al. Genome-wide loss-of-function screen reveals an important role for the proteasome in HDAC inhibitor-induced apoptosis. Cancer Cell 2009; 15: 57-66.
52. Yue Z, Jin S, Yang C, Levine AJ, Heintz N. Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor. Proc Natl Acad Sci USA 2003; 100: 15077-15082. (Pubitemid 37518019)
53. Hippert MM, O'Toole PS, Thorburn A. Autophagy in cancer: good, bad, orboth? Cancer Res 2006; 66: 9349-9351.
54. Amaravadi RK, Yu D, Lum JJ, Bui T, Christophorou MA, Evan GI et al. Autophagy inhibition enhancestherapy-induced apoptosis in a Myc-induced model of lymphoma. J Clin Invest 2007; 117: 326-336. (Pubitemid 46203961)
55. Bellodi C, Lidonnici MR, Hamilton A, Helgason GV, Soliera AR, Ronchetti M et al. Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. J Clin Invest 2009; 119: 1109-1123.
56. Luo M, Kelley MR. Inhibition of the human apurinic/apyrimidinic endonuclease (APE1) repair activity and sensitization of breast cancer cells to DNA alkylating agentswith lucanthone. Anticancer Res 2004; 24: 2127-2134. (Pubitemid 39166286)
57. Carew JS, Espitia CM, Esquivel 2nd JA, Mahalingam D, Kelly KR, Reddy G et al. Lucanthone is a novel inhibitor of autophagy that induces cathepsin D-mediated apoptosis. J Biol Chem 2011; 286: 6602-6613.
58. Yu H, Jove R. The STATs of cancer\-new molecular targets come of age. Nat Rev Cancer 2004; 4: 97-105. (Pubitemid 38198738)
59. Yu H, Pardoll D, Jove R. STATs incancer inflammation and immunity: A leading rolefor STAT3. Nat Rev Cancer 2009; 9: 798-809.
60. Kramer OH, Knauer SK, Greiner G, Jandt E, Reichardt S, Guhrs KH et al. A phosphorylation-acetylation switch regulates STAT1 signaling. Genes Dev 2009; 23: 223-235.
61. Zhang C, Richon V, Ni X, Talpur R, Duvic M. Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. J Invest Dermatol 2005; 125: 1045-1052.
62. Fantin VR, Loboda A, Paweletz CP, Hendrickson RC, Pierce JW, Roth JA et al. Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma. Cancer Res 2008; 68: 3785-3794.
63. Duvic M, Talpur R, Ni X, Zhang C, Hazarika P, Kelly C et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007; 109: 31-39. (Pubitemid 46053039)
64. Shakespear MR, Halili MA, Irvine KM, Fairlie DP, Sweet MJ. Histonedeacetylases as regulators of inflammation and immunity. Trends Immunol 2011; 32: 335-343.
65. Weichert W. HDAC expression and clinical prognosis in human malignancies. Cancer Lett 2009; 280: 168-176.
66. Nakagawa M, Oda Y, Eguchi T, Aishima S, Yao T, Hosoi F et al. Expression profile of class I histone deacetylases in human cancer tissues. Oncol Rep 2007; 18: 769-774.
67. Sasaki H, Moriyama S, Nakashima Y, Kobayashi Y, Kiriyama M, Fukai I et al. Histone deacetylase 1 m RNA expression in lungcancer. Lung Cancer 2004; 46: 171-178. (Pubitemid 39330411)
68. Miyake K, Yoshizumi T, Imura S, Sugimoto K, Batmunkh E, Kanemura H et al. Expression of hypoxia-induciblefactor-1alpha, histonedeacetylase 1, and metastasis-associated protein 1 in pancreatic carcinoma: correlation with poor prognosis with possible regulation. Pancreas 2008; 36: e1-e9. (Pubitemid 351440946)
69. Krusche CA, Wulfing P, Kersting C, Vloet A, Bocker W, Kiesel L et al. Histone deacetylase-1 and -3 protein expression in human breast cancer: A tissue microarray analysis. Breast Cancer Res Treat 2005; 90: 15-23. (Pubitemid 40486997)
70. Sudo T, Mimori K, Nishida N, Kogo R, Iwaya T, Tanaka F et al. Histone deacetylase 1 expression in gastric cancer. Oncol Rep 2011; 26: 777-782.
71. Minamiya Y, Ono T, Saito H, Takahashi N, Ito M, Mitsui M et al. Expression of histone deacetylase 1 correlates with a poor prognosis in patients with adenocarcinoma of the lung. Lung Cancer 2011; 74: 300-304.
72. Theocharis S, Klijanienko J, Giaginis C, Rodriguez J, Jouffroy T, Girod A et al. Histone deacetylase-1 and -2 expression in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patients survival. J Oral Pathol Med 2011; 40: 706-714.
73. Wu LM, Yang Z, Zhou L, Zhang F, Xie HY, Feng XW et al. Identification of histone deacetylase 3 as a biomarker for tumor recurrence following liver transplantation in HBV-associated hepatocellular carcinoma. PLo S One 2010; 5: e14460.
74. Zhang Z, Yamashita H, Toyama T, Sugiura H, Ando Y, Mita K et al. Quantitation of HDAC1 m RNA expression in invasive carcinoma of the breast*. Breast Cancer Res Treat 2005; 94: 11-16. (Pubitemid 41416937)
75. Oehme I, Deubzer HE, Lodrini M, Milde T, Witt O. Targeting of HDAC8 and investigational inhibitors in neuroblastoma. Expert Opin Investig Drugs 2009; 18: 1605-1617.
76. Marquard L, Gjerdrum LM, Christensen IJ, Jensen PB, Sehested M, Ralfkiaer E. Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma. Histopathology 2008; 53: 267-277.
77. Ozdag H, Teschendorff AE, Ahmed AA, Hyland SJ, Blenkiron C, Bobrow L et al. Differential expression of selected histone modifier genes in human solid cancers. BMC Genomics 2006; 7: 90.
78. Osada H, Tatematsu Y, Saito H, Yatabe Y, Mitsudomi T, Takahashi T. Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lungcancer patients. Int JCancer 2004; 112: 26-32. (Pubitemid 39249488)
79. Stimson L, La Thangue NB. Biomarkers for predicting clinical responses to HDAC inhibitors. Cancer Lett 2009; 280: 177-183.
80. Ellis L, Pan Y, Smyth GK, George DJ, Mc Cormack C, Williams-Truax R et al. Histone deacetylase inhibitor panobinostat induces clinical responses with associated altera-tions in gene expression profiles in cutaneous T-cell lymphoma. Clin Cancer Res 2008; 14: 4500-4510.
81. Miyanaga A, Gemma A, Noro R, Kataoka K, Matsuda K, Nara M et al. Antitumor activity of histone deacetylase inhibitors in non-small cell lung cancer cells: devel-opment of a molecular predictive model. Mol Cancer Ther 2008; 7: 1923-1930.
82. Dejligbjerg M, Grauslund M, Christensen IJ, Tjornelund J, Buhl Jensen P, Sehested M. Identification of predictive biomarkers for the histone deacetylase inhibitor belinostat in a panel of human cancer cell lines. Cancer Biomark 2008; 4: 101-109. (Pubitemid 351712270)
83. Khan O, Fotheringham S, Wood V, Stimson L, Zhang C, Pezzella F et al. HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-basedtherapy. Proc Natl Acad Sci U SA 2010; 107: 6532-6537.
84. Plumb JA, Finn PW, Williams RJ, Bandara MJ, Romero MR, Watkins CJ et al. Pharmacodynamic response and inhibition of growth of human tumor xenografts by thenovel histonedeacetylase inhibitor PXD101. Mol Cancer Ther 2003; 2: 721-728.
85. Steele NL, Plumb JA, Vidal L, Tjornelund J, Knoblauch P, Rasmussen A et al. A phase I pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin Cancer Res 2008; 14: 804-810. (Pubitemid 351231163)
86. Stimson L, La Thangue NB. Biomarkers for predicting clinical responses to HDAC inhibitors. Cancer Lett 2009; 280: 177-183.
87. Olsen EA, Kim YH, Kuzel TM, Pacheco TR, Foss FM, Parker S et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 2007; 25: 3109-3115. (Pubitemid 47218059)
88. Khan O, La Thangue NB. Drug Insight: histone deacetylase inhibitor-based therapies for cutaneous T-cell lymphomas. Nat Clin Pract Oncol 2008; 5: 714-726.
89. Kirschbaum M, Frankel P, Popplewell L, Zain J, Delioukina M, Pullarkat Vet al. Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2011; 29: 1198-1203.
90. Blumenschein Jr GR, Kies MS, Papadimitrakopoulou VA, Lu C, Kumar AJ, Ricker JL et al. Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suber-oylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer. Invest New Drugs 2008; 26: 81-87.
91. Bradley D, Rathkopf D, Dunn R, Stadler WM, Liu G, Smith DC et al. Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: A study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 Consortium. Cancer 2009; 115: 5541-5549.
92. Galanis E, Jaeckle KA, Maurer MJ, Reid JM, Ames MM, Hardwick JS et al. Phase II trial of vorinostat in recurrent glioblastoma multiforme: A north central cancer treatment group study. J Clin Oncol 2009; 27: 2052-2058.
93. Kirschbaum MH, Goldman BH, Zain JM, Cook JR, Rimsza LM, Forman SJ et al. A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest Oncology Group Study S0517. Leuk Lymphoma (e-pub ahead of print 19 September 2011).
94. Schaefer EW, Loaiza-Bonilla A, Juckett M, Di Persio JF, Roy V, Slack J et al. A phase 2 study of vorinostat in acute myeloid leukemia. Haematologica 2009; 94: 1375-1382.
95. Luu TH, Morgan RJ, Leong L, Lim D, Mc Namara M, Portnow J et al. A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: A California Cancer Consortium study. Clin Cancer Res 2008; 14: 7138-7142.
96. Traynor AM, Dubey S, Eickhoff JC, Kolesar JM, Schell K, Huie MS et al. Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: A Wisconsin Oncology Network phase II study. J Thorac Oncol 2009; 4: 522-526.
97. Modesitt SC, Sill M, Hoffman JS, Bender DP. A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Groupstudy. Gynecol Oncol 2008; 109: 182-186.
98. Woyach JA, Kloos RT, Ringel MD, Arbogast D, Collamore M, Zwiebel JA et al. Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma. J Clin Endocrinol Metab 2009; 94: 164-170.
99. Whittaker SJ, Demierre MF, Kim EJ, Rook AH, Lerner A, Duvic M et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol 2010; 28: 4485-4491.
100. Piekarz RL, Frye R, Prince HM, Kirschbaum MH, Zain J, Allen SLet al. Phase 2 trial of romidepsin in patientswith peripheral T-cell lymphoma. Blood 2011; 117: 5827-5834.
101. Niesvizky R, Ely S, Mark T, Aggarwal S, Gabrilove JL, Wright JJ et al. Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma. Cancer 2011; 117: 336-342.
102. Iwamoto FM, Lamborn KR, Kuhn JG, Wen PY, Yung WK, Gilbert MR et al. A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malig-nant glioma: North American Brain Tumor Consortium Study 03-03. Neuro Oncol 2011; 13: 509-516.
103. Molife LR,Attard G, Fong PC, Karavasilis V, Reid AH, Patterson Set al. Phase II,two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC). Ann Oncol 2010; 21: 109-113.
104. Otterson GA, Hodgson L, Pang H, Vokes EE. Phase II studyof the histonedeacetylase inhibitor romidepsin in relapsed small cell lungcancer (Cancerand Leukemia Group B 30304). J Thorac Oncol 2010; 5: 1644-1648.
105. Whitehead RP, Rankin C, Hoff PM, Gold PJ, Billingsley KG, Chapman RA et al. Phase II trial of romidepsin (NSC-630176) in previouslytreated colorectal cancer patients with advanced disease: A Southwest Oncology Group study (S0336). Invest New Drugs 2009; 27: 469-475.
106. Stadler WM, Margolin K, Ferber S, Mc Culloch W, Thompson JA. A phase II study of depsipeptide in refractory metastatic renal cell cancer. Clin Genitourin Cancer 2006; 5: 57-60.
107. Shao W, Growney JD, Feng Y, O'Connor G, Pu M, Zhu W et al. Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma models: Defining molecularmechanismsofresistance. Int JCancer 2010; 127: 2199-2208.
108. Ocio EM, Vilanova D, Atadja P, Maiso P, Crusoe E, Fernandez-Lazaro D et al. In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasonewith either bortezomib or lenalidomide in multiple myeloma. Haema-tologica 2010; 95: 794-803.
109. Dickinson M, Ritchie D, De Angelo DJ, Spencer A, Ottmann OG, Fischer T et al. Preliminary evidence of disease response to the pan deacetylase inhibitor panobino-stat (LBH589) in refractory Hodgkin Lymphoma. Br JHaematol 2009; 147: 97-101.
110. Hainsworth JD, Infante JR, Spigel DR, Arrowsmith ER, Boccia RV, Burris HA. Aphase II trial of panobinostat, a histone deacetylase inhibitor, in the treatment of patients with refractorymetastatic renal cell carcinoma. Cancer Invest 2011; 29: 451-455.
111. Walewski J, Paszkiewicz-Kozik E, Borsaru G, Moicean A, Warszewska A, Strobel K et al. Resminostat in relapsed or refractory Hodgkin lymphoma: initial results of the SAPHIRE phase II trial with a Novel Oral Histone Deacetylase (HDAC) Inhibitor. ASH Annu Meet Abstr 2010; 116: 2811.
112. Bitzer M, Horger M, Ebert MP, Ganten T, Woerns MA, Hauns B et al. First clinical data of resminostat, a novel oral histone deacetylase (HDAC) inhibitor, in patients with hepatocellular carcinoma (HCC): the SHELTER study. ASCO Meet Abstr 2010; 28 (Suppl): e14661.
113. Cashen A, Juckett M, Jumonville A, Litzow M, Flynn PJ, Eckardt J et al. Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS). Ann Hematol (e-pub ahead of print 3 May 2011).
114. Giaccone G, Rajan A, Berman A, Kelly RJ, Szabo E, Lopez-Chavez A et al. Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors. J Clin Oncol 2011; 29: 2052-2059.
115. Mackay HJ, Hirte H, Colgan T, Covens A, Mac Alpine K, Grenci P et al. Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithe-lial ovarian cancer and micropapillary (LMP) ovariantumours. Eur JCancer 2010; 46: 1573-1579.
116. Ramalingam SS, Belani CP, Ruel C, Frankel P, Gitlitz B, Koczywas M et al. Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second linetherapy of advanced malignant pleural mesothelioma. J Thorac Oncol 2009; 4: 97-101.
117. Galli M, Salmoiraghi S, Golay J, Gozzini A, Crippa C, Pescosta N et al. A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma. Ann Hematol 2010; 89: 185-190.
118. Hauschild A, Trefzer U, Garbe C, Kaehler KC, Ugurel S, Kiecker F et al. Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophe-nyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma. Melanoma Res 2008; 18: 274-278.
119. Knipstein J, Gore L. Entinostat for treatment of solid tumors and hematologic malignancies. Expert Opin Investig Drugs 2011; 20: 1455-1467.
120. Boumber Y, Younes A, Garcia-Manero G. Mocetinostat (MGCD0103): A review of an isotype-specific histone deacetylase inhibitor. Expert Opin Invest Drugs 2011; 20: 823-829.
121. Gore SD, Baylin S, Sugar E, Carraway H, Miller CB, Carducci M et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res 2006; 66: 6361-6369.
122. Kuendgen A, Schmid M, Schlenk R, Knipp S, Hildebrandt B, Steidl C et al. The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia. Cancer 2006; 106: 112-119. (Pubitemid 43032555)
123. Jagannath S, Dimopoulos MA, Lonial S. Combined proteasome and histone deacety-lase inhibition: A promising synergy for patients with relapsed/refractory multiple myeloma. Leuk Res 2010; 34: 1111-1118.
124. Munster PN, Thurn KT, Thomas S, Raha P, Lacevic M, Miller A et al. A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br J Cancer 2011; 104: 1828-1835.
125. Badros A, Burger AM, Philip S, Niesvizky R, Kolla SS, Goloubeva Oet al. Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma. Clin Cancer Res 2009; 15: 5250-5257.
126. Daud AI, Dawson J, De Conti RC, Bicaku E, Marchion D, Bastien S et al. Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial. Clin Cancer Res 2009; 15: 2479-2487.
127. Rocca A, Minucci S, Tosti G, Croci D, Contegno F, Ballarini M et al. A phase I-II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patientswith advanced melanoma. Br JCancer 2009; 100: 28-36.
128. Fakih MG, Fetterly G, Egorin MJ, Muindi JR, Espinoza-Delgado I, Zwiebel JA et al. A phase I, pharmacokinetic, and pharmacodynamic studyoftwo schedules of vorinostat in combination with 5-fluorouracil and leucovorin in patients with refractory solid tumors. Clin Cancer Res 2010; 16: 3786-3794.
129. Wilson PM, El-Khoueiry A, Iqbal S, Fazzone W, La Bonte MJ, Groshen S et al. A phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previouslyfailed 5-FU-based chemotherapy. Cancer Chemother Pharmacol 2010; 65: 979-988.